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Introduction: Bleeding occurs frequently in liver surgery. Unbalance between tissue
plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) concentrations
might increase bleeding. Our aim was to analyze perioperative fibrinolytic changes during
liver surgery.
Materials and Methods: We evaluated 15 patients for inclusion into a prospective pilot
study of liver surgery. We assessed fibrinolysis by plasma PAI-1 and t-PA: before surgery
(T1), before Pringle maneuver (PM;T2), at the end of surgery (T3) and 24 h postoperatively
(T4), and registered demographic and laboratory data, extent and duration of surgery,
hemodynamic parameters, blood loss, and transfused volumes of blood products. Data
presented as mean ± SD. Significance at P < 0.05.
Results: After exclusion of six patients only undergoing biopsies, we included six women
and three men aged 49.1 ± 19.6 years; two patients with liver metastases of colorectal
cancer and hepatocellular carcinoma, respectively, two with focal nodular hyperplasia,
two with hepatic hemangioma, and one with angiomyolipoma. Six patients underwent
PM. PAI-1 plasma concentration (n = 9) rose from 6.25 ± 2.25 at T1 through 17.30
± 14.59 ng/ml at T2 and 28.74 ± 20.4 (p = 0.007) and 22.5 ± 16.0 ng/ml (p = 0.04),
respectively, at T3 and T4. Correspondingly, t-PA plasma concentration (n= 9) increased
from 4.76± 3.08 ng/ml at T1 through 8.00± 5.10 ng/ml (p= 0.012) at T2 and decreased
to 4.25 ± 2.29 ng/ml and 3.04 ± 3.09 at T3 and T4, respectively. Plasma t-PA level at
T2 was significantly different from those at T1, T3, and T4 (p < 0.004). In PM patients,
t-PA levels increased from T1, peaked at T2 (p = 0.001), and subsequently decreased
at T3 and T4 (p = 0.011 and p = 0.037), respectively. Mean blood loss was 1,377.7 ±
1,062.8ml; seven patients received blood products. Patients with higher PAI-1 levels at
T3 received more fresh frozen plasma (r = 0.79; p = 0.01) and red blood cells (r = 0.88;
p = 0.002).
Conclusions: During liver surgery, fibrinolysis increased, as evidenced by rises in plasma
PAI-1and t-PA, especially after start of surgery and following PM. Transfused volumes of
blood products correlated with higher plasma concentrations of PAI-1. Confirming this
tendency requires a larger cohort of patients.
Keywords: fibrinolysis, liver surgery, tissue plasminogen activator, t-PA, plasminogen activator inhibitor type 1,
PAI-1
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INTRODUCTION
Liver resection is a commonly used procedure for treatment of
both benign and malignant hepatic diseases. Although, both
anesthetic and surgical techniques have progressed during the
last few years, resulting in lower perioperative morbidity, serious
complications still occur (1).
The liver is involved in synthesis and clearance of proteins of
the fibrinolytic system, which is responsible for the degradation
of thrombi in the vasculature (2–4). Fibrinolysis starts with
activation of the enzyme tissue plasminogen activator (t-PA),
which converts plasminogen to plasmin on the fibrin surface. The
concentration of t-PA in blood is regulated by its rate of secretion
by endothelial cells, its hepatic clearance, and its inhibition
mainly by plasminogen activator inhibitor-1 (PAI-1). It is well
established that hyperfibrinolysis occurs in 30–50% of patients
undergoing liver surgery (5, 6). Thus, bleeding is one of the most
common complications, and it is in most cases unpredicted (7).
To reduce bleeding during liver resection, the surgeon often
uses the so-called Pringle maneuver (PM), which consists in
clamping the hepatoduodenal ligament, thereby interrupting
blood flow through the hepatic artery and portal vein (8). In the
case of severe blood losses, blood transfusionsmay bemandatory.
Blood transfusions are associated with a higher mortality and
morbidity in patients that are prone to liver resection or other
causes of hepatic bleeding (9, 10).
Hepatic bleeding might occur, not only following activation of
fibrinolysis, but also secondary to reduced production or rapid
consumption of coagulation factors. Hence, limited reserves of
coagulation proteins might play a decisive role for the outcome
when bleeding occurs in patients with liver diseases (7, 11, 12).
However, in liver surgery, it is difficult to sort out whether
the bleeding results from changes in hemostasis alone, or to
concomitantly occurring hyperfibrinolysis (13–16).
In the present prospective pilot study, we speculate, whether
increased fibrinolysis develops secondary to low liver clearance
of tissue plasminogen activator (t-PA) in combination with
protein C inactivation of PAI-1 (17). These adjustments might
promote the conversion of plasminogen into plasmin resulting
in a distortion of the balance between t-PA and PAI-1; thus,
stimulating increased bleeding during and after liver surgery
(1, 7, 18). Changes in the plasma concentrations of PAI-1 and t-
PA counted as primary end-points while the associations between
the latter, the extent of liver surgery and the amount of transfused
blood products served as secondary end-points. Finally, we also
aimed at calculating the sample size of a future prospective study
of perioperative fibrinolysis in liver surgery.
MATERIALS AND METHODS
Population
Fifteen subsequent patients, who were scheduled for liver
resection surgery, were included in a prospective pilot
observational study in Pauls Stradins Clinical University
Hospital in Riga, Latvia. TheMedical Research Ethics Committee
approved the study protocol and the informed consent form
(Approval No 125/28.01.2016).
We defined the following exclusion criteria: patients<18 years
of age, tumor considered as being radically inoperable or surgery
limited to tumor biopsy only (5 patients) or cholecystectomy
(1 patient). Therefore, after further analysis, we excluded six
patients, as depicted in Figure 1. We obtained informed consent
from every patient, or his or hers designated surrogates.
Perioperative Management
All patients underwent standard general anesthesia including
endotracheal intubation. We induced anesthesia by injection
of midazolam 2.5mg (Dormicum R©, F. Hoffman-La Roche AG,
Switzerland), fentanyl (Fentanyl-Kalceks R© 0.05 mg/ml, A/S
Kalceks, Latvia) 0.01 mg/kg, atracurium (Tracrium R© 2 mg/ml,
GlaxoSmithKline Manufacturing, S.Polo, Torrile PR, Italy) 0.5
mg/kg and propofol (Propofol-Lipuro R© 10 mg/ml, B. Braun
Melsungen AG, Germany) 1.5–2 mg/kg intravenously.
Anesthesia was maintained with inhalation of sevoflurane
(Sevoflurane R©, Piramal Healthcare Ltd, United Kingdom) at
0.8–1.2 MAC, combined with continuous infusion of fentanyl
(Fentanyl-Kalceks R© 0.05 mg/ml, A/S Kalceks, Latvia) 0.01–0.03
mg/kg/min. Muscle relaxation was obtained with atracurium
0.25 mg/kg per h. All patients received tranexamic acid (TXA)
(Amchafibrin R© 500 mg/5ml, Rottapharam S.L., Spain) 10 mg/kg
before skin incision. We also provided postoperative epidural
analgesia with bupivacaine (Marcain R©, AstraZeneca UK Ltd.,
Macclesfield, Cheshire SK10 2NA UK) 0.5% solution 0.05–0.08
mg/kg at the end of surgery.
On purpose, we accepted relative hypovolemia during surgery,
as assessed by keeping the central venous pressure (CVP)
between 4 and 8 cmH2O to minimize bleeding. If concomitantly,
tachycardia (heart rate > 100/min), hypotension (mean blood
pressure<65mmH2O), or oliguria (< 0.5ml/kg/h) should occur,
we administered vasoactive agents, for instance, norepinephrine
or dopamine at doses of 0.05–0.2µg/kg/min and 3–7µg/kg/min,
respectively. Patients, who had blood losses of >10 ml/kg and/or
demonstrated hemodynamic instability and signs of severe
hypovolemia, including hemoglobin levels <9 g/L, received
blood transfusions.
Demographic and Laboratory Data
We collected blood from a peripheral vein into heparin tubes that
we cool centrifuged (ELMI CM-6MT R©, USA) for 5min at 3,000
× g. The plasma supernatant was removed from the spun samples
and frozen to −70◦C until the time of analysis of biomarkers of
coagulation and fibrinolysis.
We analyzed fibrinolytic activity at four data collection
points by means of the markers PAI-1 and t-PA. Firstly, we
determined baseline fibrinolytic activity before surgery (T1).
Secondly, we assessed PAI-1 and t-PA plasma concentrations
during surgery, before initiation of the Pringle maneuver (T2),
in order to evaluate the influence of surgically created tissue
damage. Thirdly, we determined the markers at the end of
surgery (T3) to assess the impact of liver hypoperfusion on
fibrinolytic activity, and fourthly, 24 h after surgery (T4), to
detect postoperative fibrinolytic activity, which commonly stays
enhanced a few days after liver resection (19).
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FIGURE 1 | Patients eligible for study of fibrinolysis in liver surgery. Six patients were excluded from the study. Nine patients were analyzed for changes in fibrinolytic
markers. t-PA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor type 1.
PAI-1 and t-PA (Technoclone Gmbh R©, Vienna Austria) were
analyzed with actibind, an ELISAmethod. Plasma concentrations
of PAI-1 and t-PA are normally <20 ng/ml and <10 ng/ml,
respectively.
In addition to PAI-1 and t-PA, we determined the fibrinogen
plasma concentration in citrated plasma (Multifibren U
reagent, Siemens Healthcare Diagnostics, USA) preoperatively
and analyzed prothrombin (PT) with a PT complex assay
(Lyophilized Dade R© and Innovin R©, Siemens Healthcare
Diagnostics, USA). We performed all the coagulation tests by
means of Sysmex R© CA-1500 (Siemens Healthcare Diagnostics,
Germany). Hemoglobin (Hb), hematocrit (Hct), platelets, white
and red blood cell counts were analyzed by means of a Beckman
Coulter LH 750 Hematology Analyzer.
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Statistical Analysis
Data were analyzed with SPSS (SPSS R© version 20, Chicago,
IL) and SigmaPlot (Systat Software, Inc., San Jose, CA), as
appropriate. Continuous variables were presented as mean ±
standard deviation (SD) or as median and interquartile range;
categorical variables as percentages (%). We checked the data
for normal distribution with Kolmogorov-Smirnov and Shapiro
Wilks tests and used ANOVA for repeated measurements
followed by Student-Newman-Keuls post-hoc test for all pairwise
multiple comparisons of PAI-1 and t-PA vs. time (T1-T4).
We used linear regression (Pearson’s correlation coefficient) to
analyze the relationships between demographic and surgical data
as well as PAI-1 and t-PA vs. bleeding volumes. Furthermore,
we used Chi-square test to analyze categorical data. We
defined a p < 0.05 as a statistically significant difference and
correspondingly, p > 0.05 as not significant (NS). We also
calculated sample sizes with comparisons of two means or paired




Totally 15 consecutive patients underwent liver resection
during a 6 months period whereof six patients met exclusion
criteria. Table 1 displays baseline demographic characteristics,
comorbidities and clinical details, such as the extent and duration
of surgery, blood loss, hemodynamic parameters, and volumes
of transfused blood products in the remaining nine patients
included in the study. We evaluated the patients as belonging to
ASA II and III since they all had co-morbidities with different
degrees of compensation.
The extent of liver resection was from one to four segments
with an average duration of surgery of 339.4 ± 230.5min (min.
190–max. 910min). The Pringle maneuver lasted from 20 to
25min (mean 20.5min). Mean CVP was 4.9 ± 1.9 cm H2O,
ranging from 2.5 to 8 cm H2O during surgery indicating relative
hypovolemia. Mean systolic blood pressure was 115.2 ± 7.5
mmHg and mean heart rate was 72± 17 beats/min.
Five patients had significant bleeding during surgery, each of
them lost more than 1,000ml of blood. Average blood loss was
1,378 ± 1,063ml. Seven patients received transfusions of packed
red blood cells and fresh frozen plasma, whereas only two of them
required fibrinogen substitution with cryoprecipitate (Table 1).
Before surgery, the patients had the following mean blood cell
counts: white blood cells 7.30 ± 1.98 × 109/L, red blood cells 4.6
± 0.33 × 1012/L, and platelets 272 ± 97.9 × 109/L. Hb and Hct
were 140.3 ± 15.3 g/L and 42 ± 3.49%, respectively. Standard
coagulation parameters were within normal ranges: activated
partial thromboplastin time (APTT) 30 ± 2.9 s, prothrombin
time (PT) 104 ± 14%, International Normalized Ratio (INR) 0.9
± 0.07 and fibrinogen plasma concentration 3.6± 0.18 g/L.
Changes in PAI-1 and t-PA Plasma
Concentrations
As shown in Figure 2A, plasma concentration of PAI-1 (n = 9)
increased from 6.25 ± 2.24 ng/ml at T1 through 17.30 ±
TABLE 1 | Baseline demographic characteristics, surgical and hemodynamic
parameters.
Demographic data Totally,
n = 9 (%)
Women,
n = 6 (%)
Men,
n = 3 (%)
Age, years 49 ± 19.6 42.5 ± 20.3 62.3 ± 11
Body weight, kg 75 ± 14.5 69 ± 13 87 ± 11.5
COMORBIDITIES
Hypertension, n (%) 6 (67%) 3 (50%) 3 (100%)
Diabetes mellitus, n (%) 6 (67%) 3 (50%) 3 (100%)
COPD, n (%) 2 (22%) 0 (0%) 2 (67%)
PRIMARY DIAGNOSIS
Metastatic colorectal cancer 2 (22%) 1 (17%) 1 (33%)
Hepatocellular carcinoma 2 (22%) 1(17%) 1 (33%)
Focal nodular hyperplasia 2 (22%) 2 (33%) 0 (0%)
Liver hemangioma 2 (22%) 1(17%) 1(33%)
Angiomyolipoma 1 (11%) 0 (0%) 1(33%)
LIVER RESECTION EXTENT
One segment 2 (22%) 1 (17%) 1 (33%)
Two segments 4 (44%) 3 (50%) 1 (33%)
Three segments 2 (22%) 2 (33%) 0
Four segments 1 (11%) 0 1 (33%)
Duration of surgery, min 339.4 ± 230.5 276 ± 96 318 ± 162
Blood loss, ml 1378 ± 1063 1216 ± 1188 1700 ± 866
HEMODYNAMIC PARAMETERS
CVP, cmH2O 4.9 ± 1.9 4.9 ± 2 5 ± 1.8
SBP, mmHg 115 ± 7.5 114 ± 4.6 117 ± 13
HR, beats/min 72 ± 17 75 ± 21 66 ± 1.4
BLOOD PRODUCT TRANSFUSIONS
Red blood cells, ml, (n) 530 ± 406 (7) 459 ± 442 (4) 672 ± 355 (3)
Freshly frozen plasma, ml, (n) 479 ± 338 (7) 459 ± 403 (4) 518 ± 218 (3)
Cryoprecipitate, ml, (n) 480 ± 28 (2) 480 ± 28 (2) 0 (0)
Data presented as mean ± SD, number (n). COPD, chronic obstructive pulmonary
disease; CVP, central venous pressure; HR, heart rate; kg, kilograms; min, minutes; ml,
milliliters; SBP, systolic blood pressure.
14.59 ng/ml during surgery before start of the Pringle maneuver
at T2 and reached its peak concentration of 28.74 ± 20.41 ng/ml
(p = 0.007) at T3. At T4, PAI-1 plasma level decreased to 22.5
± 16.2 ng/ml, but still remained elevated in comparison with T1
(p= 0.04).
Correspondingly, as depicted in Figure 2B, the plasma
concentration of t-PA (n = 9) rose from 4.76 ± 3.08 at T1 to
8.00 ± 5.1 at T2, and decreased to 4.25 ± 2.29 ng/ml and 3.04 ±
3.1 at T3 and T4, respectively. Thus, the t-PA level at T2 differed
significantly from those determined at T1, T3, and T4 (p< 0.004).
Sample Size Calculations
Weused the intragroup changes in PAI-1 concentrations between
T1 and T3, and the differences in t-PA level between T2 and T4
to calculate sample sizes of a future prospective study. Based on
mean clinical relevant intragroup differences of PAI-1 and t-PA
of 22.5 and 5.00 ng/ml, respectively, we estimated sample sizes
of 9 and 13 patients for each variable, respectively. Concerning
patients undergoing Pringle maneuver, the least sample size
Frontiers in Medicine | www.frontiersin.org 4 September 2018 | Volume 5 | Article 253
Ozolina et al. Fibrinolytic Activation in Liver Surgery
required for obtaining significant intragroup differences in PAI
between T1 and both T3 and T4, was 10 patients. Between
those who underwent Pringle maneuver at T3 vs. those who
did not, mean difference in PAI-1 was 14 ng/ml. Given standard
deviations of 19.00 ng/ml and 23.5 ng/ml, respectively, would
require 60 and 30 patients in the Pringle and the non-Pringle
groups.
Relationships Between PAI-1 Plasma
Concentrations and Volumes of Transfused
Blood Products
Statistically significant correlations were observed at T3 between
PAI-1 plasma levels and transfused volumes of fresh frozen
FIGURE 2 | (A) Plasma concentrations of PAI-1. T1, before surgery; T2,
before Pringle maneuver; T3, at the end of surgery; T4, 24 h postoperatively.
Data presented as mean ± SD (n = 9). Closed circles represent patients
subjected to the Pringle maneuver (n = 6); open circles represents subjects in
whom the Pringle maneuver was not performed (n = 3). *Denotes p < 0.05 vs.
T1 as assessed by RM ANOVA followed by pairwise multiple comparisons
(Student-Newman-Keuls method). PAI-1, plasminogen activator inhibitor, type
1. (B) Plasma concentrations of t-PA. T1, before surgery; T2, before Pringle
maneuver; T3, at the end of surgery; T4, 24 h postoperatively. Data presented
as mean ± SD (n = 9). Closed circles represent patients subjected to the
Pringle maneuver (n = 6); open circles represents subjects in whom the Pringle
maneuver was not performed (n = 3). #Denotes p < 0.05 vs. corresponding
T2 value, as assessed by RM ANOVA followed by pairwise multiple
comparisons (Student-Newman-Keuls method). t-PA, tissue plasminogen
activator.
plasma and red blood cells. As depicted in Figures 3A,B,
the patients who presented with the highest PAI-1 plasma
concentrations at T3 also received most transfusions of red blood
cells (r = 0.9; p = 0.002) and fresh frozen plasma (r = 0.8;
p = 0.01). We did not find corresponding relationships between
t-PA and transfused volumes of blood products.
Associations Between Extent of Liver
Resection and PAI-1 and t-PA Plasma
Concentrations at the End of Surgery
Plasma concentrations of PAI-1 increased gradually with the
extent of liver resections, albeit without reaching statistical
significant difference. At the end of surgery (T3), mean PAI-1
plasma concentration was 13.6 ± 19 ng/ml in patients subjected
to resection of one liver segment, and correspondingly 29 ±
19 ng/ml after resection of two segments, and 34.7 ± 32 ng/ml
and 45 ng/ml after three and four liver segment resections,
respectively.
FIGURE 3 | (A) Correlation between PAI-1 and transfused volume of red
blood cells at the end of liver surgery (T3). Data presented as Pearson
correlation coefficient (r) with p-value. PAI-1, plasminogen activator inhibitor,
type 1. (B) Correlation between PAI-1 and transfused volume of fresh frozen
plasma at the end of liver surgery (T3). Data presented as Pearson correlation
coefficient (r) with p-value. PAI-1, plasminogen activator inhibitor, type 1.
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A similar tendency, was seen when analyzing the
corresponding t-PA plasma concentrations. At the end of
surgery (T3), t-PA was 3 ± 4.1 ng/ml in patients subjected to
resection of a single liver segment, and 4.7 ± 1.3 ng/ml and 5.2
± 3.5 ng/ml, respectively, in those who underwent two and three
segment resections. Surprisingly, we found the lowest t-PA level
of 2.9 ng/ml in the patient with four liver segment resections.
Effects of Pringle Maneuver on PAI-1 and
t-PA
We also compared PAI-1 and t-PA plasma concentrations after
surgery at T3 in patients subjected to the Pringle maneuver
(n = 6) with those in whom the maneuver was not applied
(n = 3). In those exposed to the Pringle maneuver, PAI-1 plasma
concentration increased from 7.00 ± 2.37 ng/ml at T1 to 24.05
± 19.16 ng/ml (NS) at T3, and further to 26.66 ± 18.17 ng/ml
(NS) at T4. In subjects not exposed to the Pringle maneuver, PAI-
1 increased significantly within group from 4.76 ± 1.05 ng/ml at
T1 to 38.13± 23.46 ng/ml at T3 (p= 0.043), and decreased to 14
± 7 ng/ml (NS) at T4.
In patients subjected to the Pringle maneuver, plasma t-PA
levels increased from 4.36 ± 2.68 ng/ml at T1 through 9.33 ±
4.53 ng/ml at T2 (p = 0.001), and subsequently decreased to
3.78 ± 2.30 at T3 (p = 0.011 vs. T2) and to 2.93 ± 3.14 ng/ml
(p = 0.037 vs. T2) at T4. In patients not undergoing the Pringle
maneuver, t-PA fell slightly from 5.56 ± 4.30 ng/ml at T1 to 5.20
± 2.40 ng/ml at T3 and to 3.26± 3.68 ng/ml at T4 (NS). However,
we found no intergroup differences in PAI-1 and tPA plasma
concentrations depending on whether the Pringle maneuver was
used or not.
DISCUSSION
In patients subjected to liver surgery, we observed increments
in fibrinolytic activity, as assessed by changes in plasma
concentrations of PAI-1 and t-PA. In nine patients undergoing,
at least, one segment resection, we found significant associations
after surgery between PAI-1 plasma levels and volumes of
transfused red blood cells and fresh frozen plasma. However, we
noticed no such associations with t-PA.
The liver is responsible for synthesis and clearance of several
hemostatic factors. Increased fibrinolytic activity occurs as a
shift in the balance between pro-fibrinolytic (t-PA) and anti-
fibrinolytic (PAI-1) factors, as characterized by an increase in
global fibrinolytic capacity and a reduction of clot lysis time,
particularly in patients with liver cirrhosis (11). Liver surgery
on its own right, and the use of the Pringle maneuver with
major endothelial damage, can reduce hepatic perfusion, increase
hepatocellular dysfunction and promote a hyper-fibrinolytic state
(8, 20, 21). Therefore, prophylaxis with anti-fibrinolytic agents
are recommended in patients scheduled for liver surgery (22–
24). Although, all the patients received a prophylactic dose of
10 mg/kg of tranexamic acid after induction of anesthesia, its
modulating effect on the activation of fibrinolysis and bleeding
is still questionable.
As a part of our preoperative routines, we evaluated the
perioperative morbidity and mortality risks by means of the
Child-Pugh score, which is widely used to assess the prognosis
of patients with liver cirrhosis (25). With a score of less than 6
points, corresponding to a Child–Pugh class A, we predicted the
one-year survival rate of our patients to 100% (26, 27). Therefore,
we considered the perioperative mortality risk as low, which we
also confirmed by observing that no patient died or experienced
serious complications during or after the surgery.
It is well documented that the plasma level of t-PA, the main
fibrinolytic activator responsible for the cleavage of plasminogen
to plasmin, is elevated in patients with chronic liver disease (5).
We observed no elevations in t-PA before the surgery, except
for in one patient, in whom plasma t-PA was 10.5 ng/ml at T1
increasing to 12.5 ng/ml at T2. The latter patient, who underwent
resection of three segments in an operation lasting for more
than 6 h, also presented with a blood loss of 2,300ml, which
was the second highest in the group. Another patient, who
underwent segment resection, which lasted for more than 3 h,
had no increase in t-PA preoperatively, but displayed an elevated
concentration of 10.5 ng/ml at T2, which was associated with
a blood loss of 2,200ml. However, we were not able to find
any significant correlations between bleeding volumes and t-PA
plasma concentrations in the patient population as a whole.
Trauma and tissue hypoperfusion might trigger traumatic
coagulopathy. Following trauma and tissue hypoperfusion,
thrombin activates protein C on the surface of endothelial cells
via the endothelial protein C receptor and the membrane-
bound glycoprotein thrombomodulin, forming the thrombin–
thrombomodulin complex. Low plasma protein C levels and high
plasma thrombomodulin levels are associated with increased
mortality (28). Vascular endothelial cells, smooth muscle cells,
hepatocytes, and platelets produce PAI-1, an acute phase protein
and major inhibitor of t-PA, in response to sepsis, various
cytokines, surgery and trauma (29).After activation of protein
C, PAI-1 might fall below normal level (7). However, in
our patients, mean plasma concentration of PAI-1 before the
surgery was within the normal range (5–20 ng/ml). Moreover, as
depicted in Figures 3A,B, patients who had higher PAI-1 plasma
concentrations at T3, also received significantlymore fresh frozen
plasma and red blood cell transfusions. Presently, it is not known,
whether a low plasma PAI-1 level is predictive of clinical outcome
after a major blood loss such as during haemorhagic shock.
We observed the most rapid increments in marker plasma
concentrations at the beginning of surgery. PAI-1 increased
nearly three-fold when comparing the concentration determined
at T1 with that found at T2 and almost 5-fold, as compared with
that at the end of surgery (T3). We interpret these changes as
secondary to activation of the fibrinolytic system in the presence
of an insufficient inhibition. Increments in the concentration of
t-PA were rather modest, as assessed by an elevation of 68%
at T2 as compared with that at T1. Rapid increments in these
marker concentrations at the start of surgery might be explained
by endothelial and surgical tissue damages, as described by recent
investigators (1, 30).
Our findings are consistent with those of Illig and co-authors,
who studied primary fibrinolysis during supraceliac clamping of
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the aorta (31). The latter included 10 consecutive patients and
compared them with eight controls, who underwent infra-renal
clamping of the aorta during abdominal aortic reconstruction
surgery. Supraceliac clamping rapidly induced a primary
fibrinolytic state characterized by increased circulating t-PA and
reduced alpha 2-antiplasmin. The investigators interpreted their
findings as secondary to hepatic hypoperfusion. In the present
study, the Pringle maneuver was associated with a significant
increase in t-PA plasma concentration after the surgery. This
observation is consistent with findings reported by other
recent researchers (32–34). The latter investigators demonstrated
that the Pringle maneuver might intensify hepatic ischemia,
reperfusion injury, and blood vessel trauma. Consequently, it
promotes t-PA secretion from endothelial cells in response to
a variety of noxious stimuli such as exposure to endotoxin,
arterial ischemia and venous occlusion (27, 35). According
to recent recommendations, the Pringle maneuver should be
performed intermittently limited to a duration of no more
than 1 h (36). Therefore, we performed the Pringle maneuver
within a time limit of 30min. However, we were not able to
display a correlation between fibrinolytic markers and time of
clamping.
According to recent studies, mean blood loss in otherwise
healthy patients undergoing liver surgery is ∼600–900ml, which
is less than in our patients. We found a blood loss ranging from
100 to 3,000ml. This discrepancy might be due to comorbidities
and a high age difference between the patients, combined with the
fact that liver resection surgery in Latvia was implemented rather
recently (30, 37).
After analyzing the influence of the extent of tissue resection
on fibrinolytic activity, we observed that in patients with more
extensive liver resections, PAI-1 plasma concentrations increased
before application of the Pringle maneuver and at the end of
surgery, which might be explained by a larger surgical tissue
trauma. Thus, apparently, the extent of liver surgery influenced t-
PA plasma levels to a lesser degree. According to recent literature,
fibrinolytic activity might increase before surgery in patients with
chronic liver diseases, as documented by elevated t-PA plasma
levels (30).
Surprisingly, the patient with a four segment liver resection
had a low t-PA plasma level at the end of surgery and 24 h
postoperatively. Most likely, this is explained by a decrease in
hepatic clearance and low t-PA plasma levels already before the
surgery. Low plasma levels of t-PA at baseline could be due
to high age and such co-morbidities as general atherosclerosis,
arterial hypertension, type 1 diabetes and metabolic syndrome.
These co-morbidities were frequently associated with reduced
levels of t-PA and elevated PAI-1 concentrations (38). However,
in the present study, we observed lower t-PA and higher PAI-1
levels already before the surgery.
We admit as a major limitation that the study is undersized to
detect significant intragroup differences in t-PA and intergroup
differences in both PAI-1 and t-PA between patients who
underwent the Pringle maneuver and those who did not.
The reason for this shortage is that we introduced systematic
liver surgery rather recently. Moreover, because of limited
experience both with anesthetic and surgical management of
patients undergoing liver surgery we intentionally avoided to
include a control group not given the prophylactic standard
dose of tranexamic acid. This kind of surgery requires
multidisciplinary treatment and application of demanding
techniques, which in addition to patient factors explain both the
small number of patients included, and the relatively high blood
losses.
Another limitation is the heterogenic group of patients
studied. Some of them had different co-morbidities such as
diabetes, primary arterial hypertension that might affect baseline
fibrinolytic activity. We do not know to what degree fibrinolytic
activation due to surgical trauma and blood loss occur in these
patients in comparison with those without such cardiovascular
co-morbidities.
Unfortunatelly, we did not meassure changes in activated
protein C plasma levels in parallel with changes in PAI-1
concentrations. Because of low sample sizes and no deaths in our
pilot study, we were not able to analyze the impact of changes in
plasma concentrations of PAI-1 onmortality or othermeasures of
clinical outcome. However, we found corelations between PAI-1
level after surgery and transfused volumes of red blood cells and
fresh frozen plasma.Considering the limited number of patients
in this pilot study and their initial Child-Pugh scores, we should
be cautious to extrapolate the results to a larger cohort of patients
scheduled for liver surgery. In accordance with our sample size
calculations, we expect that a future prospective multicenter
study of at least 90 patients planned for liver surgery, which
also includes the Pringle maneuver, might shed more light on
fibrinolysis as a cause of perioperative bleeding.
CONCLUSIONS
During liver resection surgery, fibrinolytic system activation
increases as experienced by a significant release of PAI-1, in
parallel with increments in t-PA, especially at the start of
surgery. Application of the Pringle maneuver was associated
with a trend toward more pronounced activation of fibrinolysis.
Although, we found no associations between fibrinolytic markers
and bleeding volumes, higher plasma concentrations of PAI-1
correlated highly with the volumes of transfused blood products.
Further analysis including more patients is necessary to confirm
the augmentation of fibrinolysis and its correlation with bleeding
volumes during liver surgery.
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